These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 18185488

  • 1. Temsirolimus for advanced renal cell carcinoma.
    Figlin RA.
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):893. PubMed ID: 18185488
    [No Abstract] [Full Text] [Related]

  • 2. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec 17; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract] [Full Text] [Related]

  • 3. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ, Hsu A.
    Clin J Oncol Nurs; 2008 Aug 17; 12(4):639-46. PubMed ID: 18676330
    [Abstract] [Full Text] [Related]

  • 4. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
    Jafri M, Douis H, Porfiri E.
    Clin Oncol (R Coll Radiol); 2008 Oct 17; 20(8):657-8. PubMed ID: 18644704
    [No Abstract] [Full Text] [Related]

  • 5. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA.
    Nat Clin Pract Oncol; 2008 Oct 17; 5(10):601-9. PubMed ID: 18607393
    [Abstract] [Full Text] [Related]

  • 6. Temsirolimus in renal cell carcinoma.
    Otto T, Eimer C, Gerullis H.
    Transplant Proc; 2008 Dec 17; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [Abstract] [Full Text] [Related]

  • 7. Molecule of the month. Temsirolimus.
    Drug News Perspect; 2007 Dec 17; 20(6):406. PubMed ID: 17925894
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
    Bukowski RM.
    Clin Genitourin Cancer; 2007 Sep 17; 5(6):359-61. PubMed ID: 17956708
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
    Paterson C, Jones RJ.
    Clin Oncol (R Coll Radiol); 2009 Nov 17; 21(9):732-3. PubMed ID: 19665360
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.
    Gerullis H, Bergmann L, Maute L, Eimer C, Otto T.
    Cancer Chemother Pharmacol; 2009 May 17; 63(6):1097-102. PubMed ID: 18818922
    [Abstract] [Full Text] [Related]

  • 16. Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS.
    Pal SK, Vogelzang NJ.
    Clin Genitourin Cancer; 2011 Sep 17; 9(1):3-5. PubMed ID: 21816688
    [No Abstract] [Full Text] [Related]

  • 17. Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma.
    Rodríguez Faba O, Breda A, Rosales A, Palou J, Algaba F, Maroto Rey P, Villavicencio H.
    Eur Urol; 2010 Aug 17; 58(2):307-10. PubMed ID: 20347211
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. New mTOR inhibitor for renal cell cancer.
    Wilkes GM.
    Oncology (Williston Park); 2009 Jul 17; 23(8 Suppl):54-6. PubMed ID: 19860046
    [No Abstract] [Full Text] [Related]

  • 20. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
    De Masson A, Fouchard N, Méry-Bossard L, Dauendorffer JN.
    Dermatology; 2011 Jul 17; 223(1):4-8. PubMed ID: 21846963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.